Novorapid is a bolus insulin analogue created by Novo Nordisk. It is of rDNA origin. It is sold under the name ‘Novolog’ in the United States.
It has become a widely-used replacement for the now defunct Actrapid insulin, as it has very similar properties. One problem with this insulin though is that it has to be administered in double the quantity that Actrapid was, although this is only a small problem.
It has a reaction time of around 25–35 minutes, depending on the physical size of the person taking it. This means it is known as “fast-acting”.